SCHEMBL5348590

SCHEMBL5348590

CC(c1cccc(N)n1)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
TDP1 Q9NUW8 1/20 0.41
HTT P42858 3/20 0.38
ALDH1A1 P00352 4/20 0.36
USP2 O75604 1/20 0.36
TSHR P16473 1/20 0.36
CASP3 P42574 1/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
TP53 P04637 1/20 0.35
NOS3 P29474 1/20 0.35
NOS2 P35228 1/20 0.35
XIAP P98170 1/20 0.35
BIRC2 Q13490 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9383555 0.76 LMNA (0.41) LMNATDP1ALDH1A1USP2KMT2A
Hydrochloric Acid SCHEMBL9381863 0.75 LMNA (0.40) LMNATDP1ALDH1A1USP2KMT2A
SCHEMBL31752536 0.72 CYP1A2 (0.55) LMNATDP1HTTALDH1A1USP2
SCHEMBL12184795 0.70 LMNA (0.47) LMNATDP1HTTALDH1A1TSHR
SCHEMBL179264 0.69 NOS2 (0.50) NOS3NOS2XIAPBIRC2
SCHEMBL1892274 0.69 TDP1 (0.55) LMNATDP1HTTALDH1A1TSHR
SCHEMBL7250955 0.69 ALDH1A1 (0.49) HTTALDH1A1USP2KMT2AKDM4E
SCHEMBL6925572 0.69 LMNA (0.58) LMNATDP1ALDH1A1CASP3TP53
SCHEMBL29393294 0.69 LMNA (0.58) LMNATDP1ALDH1A1CASP3TP53
SCHEMBL607042 0.69 LMNA (0.58) LMNATDP1ALDH1A1CASP3TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
EP-1309589-B1 UREA COMPOUNDS AND METHODS OF USES AMGEN INC (US) 2006-03-15 EP disclosed
EP-1619184-A2 Urea compounds as kinase inhibitors Amgen, Inc. (US) 2006-01-25 EP disclosed
US-20040044044-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-03-04 US disclosed
US-20040039029-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-02-26 US disclosed
US-6645990-B2 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases AMGEN INC. 2003-11-11 US disclosed
US-20020193405-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2002-12-19 US disclosed
US-20020173507-A1 Urea compounds and methods of uses AMGEN INC. 2002-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193405-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX LMNA 2067/4885TDP1 642/4885HTT 1348/4885
US-20020173507-A1 Urea compounds and methods of uses SLC14A1, UMPS, BAX LMNA 1241/4885TDP1 1033/4885HTT 1461/4885
US-20040039029-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX LMNA 2067/4885TDP1 642/4885HTT 1348/4885
US-20040044044-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX LMNA 2067/4885TDP1 642/4885HTT 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.